Caricamento...
Bisphosphonates or RANK‐ligand‐inhibitors for men with prostate cancer and bone metastases: a network meta‐analysis
BACKGROUND: Different bone‐modifying agents like bisphosphonates and receptor activator of nuclear factor‐kappa B ligand (RANKL)‐inhibitors are used as supportive treatment in men with prostate cancer and bone metastases to prevent skeletal‐related events (SREs). SREs such as pathologic fractures, s...
Salvato in:
| Pubblicato in: | Cochrane Database Syst Rev |
|---|---|
| Autori principali: | , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley & Sons, Ltd
2020
|
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8095056/ https://ncbi.nlm.nih.gov/pubmed/33270906 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD013020.pub2 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|